Early Detection of β-Cell Decline Using Home Dried Blood Spot C-Peptide Levels in New-Onset Type 1 Diabetes
Home DBS C-peptide assessment is a feasible method to monitor β-cell function in ND type 1 diabetes. The early prognostic utility of stimulated DBS C-peptide highlights its potential for optimizing trial design. However, further validation is needed to confirm its reliability and broader applicability.
Authors
- Emile Hendriks (ORCID: https://orcid.org/0000-0002-0795-1832)
- Lut Overbergh (ORCID: https://orcid.org/0000-0001-7126-356X)
- Keith Burling (ORCID: https://orcid.org/0000-0002-0109-7751)
- Maria Loredana Marcovecchio (ORCID: https://orcid.org/0000-0002-4415-316X)
- Chantal Mathieu (ORCID: https://orcid.org/0000-0002-6099-2406)
- Mark L. Evans
- Peter Barker
Institutions
- University of Cambridge (GB)
- Universitair Ziekenhuis Leuven (BE)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Bridge University (SS)
- Wellcome/MRC Institute of Metabolic Science (GB)
- KU Leuven (BE)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-05-22
- DOI
- https://doi.org/10.2337/dc25-0214
- Citations
- 1
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Eli Lilly and Company
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- European Federation of Pharmaceutical Industries and Associations
- Dexcom
- National Institute for Health and Care Research
- Novo Nordisk
- Innovative Medicines Initiative
- Abbott Diabetes Care
- NIHR Cambridge Biomedical Research Centre